Recombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen)

重组人源化抗Claudin 18.2单克隆抗体（科济）

Report date: 2025/04/20 20:00:03

Base Information

Drug NameRecombinant humanized anti-Claudin 18.2 monoclonal antibody (CARsgen)
Drug Alias NameAB-011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCARsgen Life Sciences Co LtdCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCarsgen Biomedicine (Shanghai) Co LtdCARsgen Life Sciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A